IL2 Cancer Research Results

IL2, Interleukin-2: Click to Expand ⟱
Source:
Type:
The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells.

IL-2 is often expressed in various cancers, including melanoma, renal cell carcinoma, and certain hematological malignancies. Its expression can vary depending on the tumor type and the immune context.
Tumor-infiltrating lymphocytes (TILs), particularly activated T cells, are significant sources of IL-2 in the tumor microenvironment.

IL-2 is primarily known for its role in promoting anti-tumor immunity. It stimulates the proliferation and activation of T cells, enhancing their ability to recognize and kill tumor cells.
HCC, Hepatocellular Carcinoma: Click to Expand ⟱
Hepatocellular Carcinoma
Scientific Papers found: Click to Expand⟱
5436- AG,    Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice
- in-vivo, HCC, NA
TumCG↓, BAX↑, Bcl-2↓, IL2↑, IL6↑, TNF-α↑, toxicity↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

BAX↑, 1,   Bcl-2↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL2↑, 1,   IL6↑, 1,   TNF-α↑, 1,  

Clinical Biomarkers ⓘ

IL6↑, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IL2, Interleukin-2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:10  Cells:%  prod#:%  Target#:366  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page